MX367850B - Prevención y tratamiento de condiciones inflamatorias. - Google Patents
Prevención y tratamiento de condiciones inflamatorias.Info
- Publication number
- MX367850B MX367850B MX2013015441A MX2013015441A MX367850B MX 367850 B MX367850 B MX 367850B MX 2013015441 A MX2013015441 A MX 2013015441A MX 2013015441 A MX2013015441 A MX 2013015441A MX 367850 B MX367850 B MX 367850B
- Authority
- MX
- Mexico
- Prior art keywords
- prevention
- treatment
- inflammatory conditions
- embodiments relate
- liver disease
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 4
- 230000004968 inflammatory condition Effects 0.000 title abstract 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 102000003702 retinoic acid receptors Human genes 0.000 abstract 2
- 108090000064 retinoic acid receptors Proteins 0.000 abstract 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000002353 alcoholic hepatitis Diseases 0.000 abstract 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960000565 tazarotene Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las presentes realizaciones se refieren a métodos para la prevención y el tratamiento de afecciones inflamatorias como la enfermedad hepática inducida por el alcohol (ALD). Mas específicamente, las presentes realizaciones se refieren a la prevención y tratamiento de ALD mediante la administración de un agonista del receptor del acido retinoico (RAR). Algunas realizaciones se refieren al uso de tazaroteno en la prevención y tratamiento de la lesión hepática inducida por el alcohol, la enfermedad hepática relacionada con el alcohol, la enfermedad del hígado graso, la esteatosis hepática, la hepatitis inducida por el alcohol o la cirrosis inducida por el alcohol.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161501139P | 2011-06-24 | 2011-06-24 | |
PCT/US2012/043875 WO2012178108A1 (en) | 2011-06-24 | 2012-06-22 | Prevention and treatment of inflammatory conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013015441A MX2013015441A (es) | 2014-09-22 |
MX367850B true MX367850B (es) | 2019-09-09 |
Family
ID=47422987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015441A MX367850B (es) | 2011-06-24 | 2012-06-22 | Prevención y tratamiento de condiciones inflamatorias. |
Country Status (13)
Country | Link |
---|---|
US (3) | US9949996B2 (es) |
EP (2) | EP3616701A1 (es) |
JP (2) | JP6441073B2 (es) |
KR (2) | KR102055395B1 (es) |
CN (2) | CN111298120A (es) |
AU (1) | AU2012272642B2 (es) |
BR (1) | BR112013033309B1 (es) |
CA (1) | CA2840272C (es) |
DK (1) | DK2723347T3 (es) |
ES (1) | ES2759584T3 (es) |
MX (1) | MX367850B (es) |
RU (1) | RU2678561C9 (es) |
WO (1) | WO2012178108A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2678561C9 (ru) | 2011-06-24 | 2019-03-05 | ДжиАрАй Био, Инк. | Предупреждение и лечение воспалительных состояний |
EP2945701B1 (en) * | 2013-01-18 | 2023-04-05 | Cornell University | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
US11191755B2 (en) | 2014-01-17 | 2021-12-07 | Cornell University | Compositions and methods for providing cardioprotective effects |
EP3094380B1 (en) | 2014-01-17 | 2021-04-28 | Cornell University | Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists |
CN106132422A (zh) | 2014-02-27 | 2016-11-16 | 莱斯拉公司 | 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法 |
EP3116318B1 (en) * | 2014-03-10 | 2019-03-13 | Cornell University | Combination therapy for head and neck cancer |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
CN114712504A (zh) | 2014-12-09 | 2022-07-08 | Gri生物有限公司 | 炎性病况的预防和治疗 |
JP2018515491A (ja) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションLycera Corporation | RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
CN107980042B (zh) | 2015-06-11 | 2021-10-08 | 莱斯拉公司 | 用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物 |
US11931327B2 (en) | 2017-07-04 | 2024-03-19 | Daiichi Sankyo Company, Limited | Drug for retinal degenerative disease associated with photoreceptor degeneration |
EP3806839A4 (en) * | 2018-06-14 | 2022-03-30 | Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") | COMPOSITIONS AND METHODS TO DELIVER CARDIOPROTECTIVE EFFECTS |
CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
WO2023044355A1 (en) * | 2021-09-15 | 2023-03-23 | Cornell University | Compositions and methods for mitigating alcohol liver disease |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE59777B1 (en) | 1985-12-04 | 1994-04-06 | Max Planck Gesellschaft | Medicaments |
JP3879938B2 (ja) * | 1994-03-31 | 2007-02-14 | 日本ケミカルリサーチ株式会社 | 抗炎症剤 |
JPH08109134A (ja) * | 1994-10-11 | 1996-04-30 | Sanwa Kagaku Kenkyusho Co Ltd | 細胞変成抑制並びに臓器毒性軽減剤 |
US6025388A (en) | 1995-04-26 | 2000-02-15 | Allergan Sales, Inc. | Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids |
US5624957A (en) * | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
IL128723A0 (en) | 1996-08-28 | 2000-01-31 | Inst Nat Sante De De La Rech M | Pharmaceutical compositions containing rar antagonists and rxr agonists |
AU756805B2 (en) | 1998-01-22 | 2003-01-23 | Zentaris Gmbh | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
JO2178B1 (en) | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of invasive diseases, using selected anti-PAR materials |
US7390795B2 (en) | 2000-12-18 | 2008-06-24 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
US7419958B2 (en) * | 2001-03-26 | 2008-09-02 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
EP1567172A2 (en) * | 2002-11-29 | 2005-08-31 | GPC Biotech AG | Formulations useful against hepatitis c virus infections |
US20050026950A1 (en) * | 2003-07-30 | 2005-02-03 | Allergan, Inc. | Methods of therapeutic treatment using retinoids to achieve consistent bioavailability |
CN1210041C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗痤疮的复方外用药物 |
WO2005120479A1 (en) * | 2004-06-09 | 2005-12-22 | Gpc Biotech Ag | Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c |
US20110118197A1 (en) * | 2005-09-29 | 2011-05-19 | Vipin Kumar Chaturvedi | Prevention of hepatic ischemic reperfusion injury by administration of sulfatides |
JP2009510124A (ja) * | 2005-09-29 | 2009-03-12 | トーリー パインズ インスティチュート フォー モルキュラー スタディーズ | 自己免疫障害の治療のためのスルファチド |
WO2007071402A1 (en) | 2005-12-23 | 2007-06-28 | Jado Technologies Gmbh | Means and methods for the treatment and prevention of allergic diseases |
DE102006019906A1 (de) | 2006-04-28 | 2007-10-31 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptable Salze zur Herstellung einer pharmazeutischen Zubereitung |
EP2097075A1 (fr) * | 2006-11-20 | 2009-09-09 | Galderma Research & Development, S.N.C. | Utilisation d'adapalène pour moduler l'expression de cd1d ou il-10. |
AU2010273261B2 (en) * | 2009-07-16 | 2013-07-25 | Stiefel Laboratories, Inc. | Tazarotene derivatives |
IT1403356B1 (it) | 2010-12-27 | 2013-10-17 | Sit La Precisa Spa Con Socio Unico | Dispositivo per il controllo dell'erogazione di un gas combustibile verso un bruciatore, particolarmente per apparecchi riscaldatori di acqua |
EP2809648B1 (en) | 2011-05-26 | 2019-04-03 | GRI Bio, Inc. | Oxygenated amino- or ammonium-containing sulfonic acid derivatives and their medical use |
RU2678561C9 (ru) | 2011-06-24 | 2019-03-05 | ДжиАрАй Био, Инк. | Предупреждение и лечение воспалительных состояний |
US9005490B2 (en) | 2012-12-14 | 2015-04-14 | Delphi Technologies, Inc. | Material for solid state sintered material |
EP2983709A1 (en) | 2013-04-08 | 2016-02-17 | Academisch Medisch Centrum | Miltefosin or perifosin for use in the treatment of ibd |
CN114712504A (zh) | 2014-12-09 | 2022-07-08 | Gri生物有限公司 | 炎性病况的预防和治疗 |
-
2012
- 2012-06-22 RU RU2014100056A patent/RU2678561C9/ru active
- 2012-06-22 CA CA2840272A patent/CA2840272C/en active Active
- 2012-06-22 KR KR1020147001610A patent/KR102055395B1/ko active IP Right Grant
- 2012-06-22 EP EP19195197.9A patent/EP3616701A1/en active Pending
- 2012-06-22 JP JP2014517228A patent/JP6441073B2/ja active Active
- 2012-06-22 CN CN202010113948.3A patent/CN111298120A/zh active Pending
- 2012-06-22 DK DK12803312T patent/DK2723347T3/da active
- 2012-06-22 EP EP12803312.3A patent/EP2723347B1/en active Active
- 2012-06-22 US US14/128,566 patent/US9949996B2/en active Active
- 2012-06-22 ES ES12803312T patent/ES2759584T3/es active Active
- 2012-06-22 MX MX2013015441A patent/MX367850B/es active IP Right Grant
- 2012-06-22 WO PCT/US2012/043875 patent/WO2012178108A1/en active Application Filing
- 2012-06-22 CN CN201280039650.6A patent/CN103732231B/zh active Active
- 2012-06-22 BR BR112013033309-0A patent/BR112013033309B1/pt active IP Right Grant
- 2012-06-22 KR KR1020197036256A patent/KR102164567B1/ko active IP Right Grant
- 2012-06-22 AU AU2012272642A patent/AU2012272642B2/en active Active
-
2017
- 2017-06-07 JP JP2017112987A patent/JP2017206523A/ja active Pending
-
2018
- 2018-03-06 US US15/913,541 patent/US10925886B2/en active Active
-
2021
- 2021-02-22 US US17/182,098 patent/US11660309B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX367850B (es) | Prevención y tratamiento de condiciones inflamatorias. | |
PH12020550759A1 (en) | Compositions and methods of use of phorbol esters | |
IL274469A (en) | Compositions, uses and methods for the treatment of metabolic disorders and diseases | |
PH12016501668A1 (en) | Compositions and methods for the reduction or prevention of hepatic steatosis | |
IN2014CN03749A (es) | ||
WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
PH12014502603A1 (en) | D-amino acid compounds for liver disease | |
EP2768535A4 (en) | Stabilized ETANERCEPT FORMULATIONS WITH XYLITOL | |
IN2014CN02736A (es) | ||
MX2014004074A (es) | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. | |
MX348933B (es) | Composiciones, formas de dosificacion y coadministracion de un compuesto agonista opioide y un compuesto analgesico. | |
IN2014DN03464A (es) | ||
GB201022049D0 (en) | Methods | |
EP3065705A4 (en) | Compositions and methods for administration of an enzyme to a subject's airway | |
WO2013033602A3 (en) | Fatty acid amides, compositions and methods of use | |
WO2013089809A3 (en) | Connectivity of rapidly disseminating epidemics | |
GB2509248A (en) | Golf handicap systems and methods to calculate a golf handicap | |
MX351994B (es) | Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico. | |
WO2014031034A8 (ru) | Фармацевтические композиции, содержащие ипидакрин и их применение для лечения нарушений потенции и других форм половой активности | |
MY169285A (en) | Enhancement in thermo-chemical formulation | |
UA65752U (ru) | Способ профилактики заболеваний репродуктивных органов у женщин с синдромом поликистозных яичников | |
UA64159U (ru) | Способ коррекции приобретенных нарушений репродуктивной функции хряков-производителей | |
TW202425963A (zh) | 巴豆酯之組成物及使用方法 | |
UA68764U (ru) | Способ улучшения сократительной функции матки коров мясных пород | |
UA67051U (ru) | Средство для защиты картофеля от болезней и колорадского жука |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |